

Overview of ACE-083 study for FSHD


ACE-083 OVERVIEW

ACE-083 is an investigational drug that inhibits selected proteins in the transforming growth factor-beta (TGF- β) superfamily involved in the regulation of muscle mass and strength. ACE-083 has been designed to increase muscle mass and strength selectively in the muscles into which the drug is injected. Acceleron is developing ACE-083 for diseases in which improved muscle strength in a specific set of muscles may provide a clinical benefit to patients. As an “investigational” drug, ACE-083 is not approved by any regulatory agency for use in any country.

PHASE 2 STUDY OVERVIEW

This phase 2 study is designed to evaluate the safety, tolerability and efficacy of ACE-083 in up to 76 adult patients with facioscapulohumeral muscular dystrophy (FSHD).

PHASE 2 STUDY DESIGN



KEY ELIGIBILITY REQUIREMENTS

This study may be appropriate to consider if you:

- Are 18 years or older
- Have genetically confirmed FSHD or have a clinical diagnosis of FSHD and a first-degree relative with genetically confirmed FSHD
- Are experiencing mild to moderate weakness in the tibialis anterior (TA) and/or biceps brachii (BB) muscles

This study is likely not a good fit if you:

- Have any other serious organ damage or serious diseases unrelated to FSHD
- Have serious heart or blood conditions
- Have any condition that would prevent MRI scanning of the TA or BB muscles, as applicable (e.g., pacemaker, knee/hip replacement, or metallic implants)

Your doctor is the best source of information about your potential treatment options. If you have questions about taking part in this clinical study, ask your doctor for more information.



For more information visit clinicaltrials.gov/show/NCT02927080
or email clinicaltrials083@acceleronpharma.com

ACE-083 is an investigational drug and is not approved by any regulatory agency for use in any country.